The UCLA Heart Failure, Mechanical Support and Heart Transplant Team presents

UCLA Heart Failure Symposium 2025 State-of-the-Art Updates & Therapies for Advanced Heart Failure

A Hybrid CME Conference

Available as both a live in-person and live virtual activity

Saturday, September 20, 2025

Marina del Rey Marriott

4100 Admiralty Way Marina del Rey, CA







UCLA Heart Failure Symposium 2025

Course Description

Heart failure affects approximately six million Americans and is the most common diagnosis for acute hospitalization in patients over 65 years. Over the next decade, we will see a dramatic increase in the number of patients in the community with advanced heart failure who can benefit from advanced therapies for complex cardiac disease. Academic medical centers, such as UCLA, have an opportunity to integrate treatment advances into a comprehensive patient-centered heart failure management program. UCLA Health wants to enhance the role of the primary care physician and primary cardiologist as the central provider for continuity of care for these complex heart failure patients.

The 13th Annual UCLA Heart Failure Symposium 2025 will:

- 1. Discuss general heart failure treatment options including short and long term mechanical circulatory support therapy, heart transplantation, pulmonary hypertension management, high risk percutaneous and structural interventions, and complex congenital heart disease management.
- Emphasize the need for developing networks linking academic centers with community physicians to manage these patients through the evolution of their disease pre and post advanced cardiac intervention.
- 3. Discuss heart failure therapies in cardio-oncology, amyloidosis and new medication updates, as well as address patient and care-provider's specific needs and perspectives.

Target Audience

Family practitioners, internists, cardiologists, pediatricians, nurses and all other healthcare professionals taking care of heart failure patients, as well as the interested lay public.

Learning Objectives

At the conclusion of the program participants will be able to:

- Identify the epidemiology and pathophysiology of heart failure and the need for mechanical circulatory support with a growing heart failure population.
- Identify indications for and management of lifelong left ventricular assist device therapy.
- Implement shared care programs with the community and co-manage patients in need of complex cardiac therapies including LVAD therapy, heart transplantation, pulmonary hypertension management, high risk percutaneous interventions, and complex congenital heart disease management.
- Discuss the comprehensive multidisciplinary care and services available to complex cardiac
 patients within the UCLA Heart Failure Program.

General Information

Saturday, September 20, 2025 7:00 am – 4:00 pm

Conference Location:

Marina del Rey Marriott (California Ballroom) 4100 Admiralty Way Marina del Rey, CA

Parking:

Valet parking \$25

In-person attendees will be provided breakfast, lunch, and reception at the meeting site.

The **UCLA Heart Failure Symposium 2025** will also be available through a live virtual meeting web platform.

- Attendees who choose to attend the live virtual activity will receive a virtual meeting link and password to access the live virtual conference.
- All registrants (live or virtual) will be provided the opportunity to review recorded sessions up to 3 weeks following the conference.
- The recorded sessions are not certified for CME credit.

Officially endorsed by the Heart Failure Society of America. The opinions presented in this educational activity do not necessarily reflect the opinions or recommendations of the HFSA.

Program Schedule

7:45	Welcome	Ali Nsair, MD
Session I: What's New in 2025 – Breakthroughs in Advanced Heart Failure		
8:00	State-of-the-Art Medical Therapies in Advanced Heart Failure: What is New in 2025	Gregg Fonarow, MD, FACC
8:20	A New Era of Organ Preservation and Procurement in Heart Transplantation: Going the Distance	Abbas Ardehali, MD, FACS
8:40	Robotic Surgical Interventions: Minimally Invasive Mitral Surgery	Richard Shemin, MD
9:00	Aortic Stenosis in Heart Failure Patients: When to Consider TAVR	Olcay Aksoy, MD
9:20	Cardiogenic Shock: From Mobile ECMO to ECPEL-LAS	Peyman Benharash, MD
9:40	Panel Discussion	
10:00	Break	
Session II: Nuts and Bolts: Everyday Prevention and Management of Heart Failure		
10:20	Afib Ablation in Heart Failure — King of the Castle	Peter Hanna, MD, PhD
10:40	Time to Relax: Novel Therapies for Hypertrophic Cardiomyopathy	Arnold S. Baas, MD, FACC, FACP
11:00	Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics	Darko Vucicevic, MD
11:20	Releasing the Brakes on the Immune system in Cancer: Implications on Myocarditis and Beyond	Eric Yang, MD
11:40	Advances In Heart Failure Therapies, Beyond 2025	Ali Nsair, MD
12:00	Panel Discussion	
12:20	Lunch	
Session III: Going the Distance: A Multidisciplinary approach to Advanced HF		
1:20	When to Refer: A Tale of Two Patients	Daniel Cruz, MD, PhD
1:50	Powering The Heart: Unlocking the Potential of Home Inotrope Therapy	UCLA Cardiomyopathy Advance Practice Nurses and Christine Bui, MD
2:20	Cardioobstetrics: Maternal Health in Cardiomyopathy Patients	Megan Kamath, MD
2:40	Pharmacologic Options for Managing Obesity in Patients with Heart Failure	Vijay Surampudi, MD, MS
3:00	Pulmonary Hypertension Management: From Surgical to Medical Therapies	Rajan Saggar, MD
3:10	Panel Discussion	
3:30	Adjourn and Reception	

David Geffen School of Medicine at UCLA

COURSE CHAIR

Ali Nsair, MD

Medical Director, Heart Transplantation and Mechanical Circulatory Support Device Services Heart Failure Interventional Cardiology

Broad Stem Cell Research Center

UCLA COURSE FACULTY AND PANEL PARTICIPANTS

Sabina Aleksandrovskaya, MSN, AGACNP-BC

Advanced Practice Nurse, Ahmanson-UCLA Cardiomyopathy Center

Olcay Aksoy, MD, FACC

Assistant Clinical Professor Interventional Cardiology UCLA Cardiovascular Medicine

Abbas Ardehali, MD, FACS

Professor of Surgery and Medicine
Division of Cardiothoracic Surgery
William E. Connor Chair in Cardiothoracic Transplantation
Director, UCLA Heart, Lung, and Heart-Lung Transplant
Programs

Arnold S. Baas, MD, FACC, FACP

Professor of Medicine
Ahmanson-UCLA Cardiomyopathy Center
Mechanical Circulatory Support and Heart Transplantation
Program

Peyman Benharash, MD, PhD

Assistant Professor in Residence
UCLA Cardiothoracic Surgery

Christine Bui, MD

Assistant Clinical Professor of Medicine Cardiac Palliative Care Program Department of Internal Medicine, UCLA

Julie W. Creaser, RN, MN, CNS, CHFN

Advanced Practice Nurse, Ahmanson-UCLA Cardiomyopathy Center

Daniel Cruz, MD, PhD

Associate Clinical Professor of Medicine Associate Director, Heart Transplant Ahmanson-UCLA Cardiomyopathy Center Mechanical Circulatory Support and Heart Transplantation Program

Gregg C. Fonarow, MD, FACC, FAHA, FHFSA

Chief, UCLA Division of Cardiology Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director, UCLA Preventative Cardiology Program The Eliot Corday Chair in Cardiovascular Medicine and Science

Peter Hanna, MD, PhD

Assistant Professor of Medicine
UCLA Cardiac Arrhythmia Center
David Geffen School of Medicine at UCLA

Megan Kamath, MD

Assistant Clinical Professor of Medicine Ahmanson-UCLA Cardiomyopathy Center Mechanical Circulatory Support and Heart Transplantation Program

Nancy Livingston, MSN, NP-C

Advanced Practice Nurse Ahmanson-UCLA Cardiomyopathy Center

Alexandra Monin, MSN, AGACNP-BC

Advanced Practice Nurse, Ahmanson-UCLA Cardiomyopathy Center

Anca Rahman, RN, MSN, NP-C

Advanced Practice Nurse, Ahmanson-UCLA Cardiomyopathy Center

Rajan Saggar, MD

Associate Professor of Medicine Director, Medical Intensive Care Unit Lung and Heart-Lung Transplant and Pulmonary Hypertension Programs

Richard J. Shemin, MD, FACC

Robert and Kelly Day Professor and Chief Cardiothoracic Surgery

UCLA Executive Vice Chairman of Surgery Co-Director of the Cardiovascular Center

Vijaya Surampudi, MD, MS

Associate Professor of Medicine Clinical Chief of Clinical Nutrition Department of Medicine

Elizabeth Vandenbogaart, MSN, ACNP-BC

Advanced Practice Nurse
Ahmanson-UCLA Cardiomyopathy Center

Darko Vucicevic, MD

Ahmanson-UCLA Cardiomyopathy Center Mechanical Circulatory Support and Heart Transplantation Program

Eric H. Yang, MD, FACC, FASE

Associate Clinical Professor of Medicine Director, UCLA Cardio-Oncology Program Associate Program Director, UCLA/Olive View/West LA VA Cardiovascular Diseases Fellowship



Course Title and Number

C07801

UCLA Heart Failure Symposium 2025 Saturday, September 20, 2025

In-Person & Virtual Registration Fees

Live Virtual Conference: \$100 Live In-Person Conference: \$125



In-person registration includes access to the course materials, breakfast, patio lunch and reception at the meeting site. **Virtual registration** includes access to the live stream virtual conference. All registrants (live or virtual) will receive access to the conference recordings up to 3 weeks following the program.

To register using a credit card or ACH/electronic transfer, please visit https://ucla.cloud-cme.com/HF2025 and click on UCLA Heart Failure Symposium.

*Credit card and check payments via phone, fax, or mail are no longer accepted.

Refunds

Due to the low enrollment fee, no refunds will be given for this conference.

Questions

If you have questions about enrollment, please call (310) 794-2620 or email: ccpd@mednet.ucla.edu.

Accreditation Statement

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The David Geffen School of Medicine at UCLA, designates this live activity for a maximum of 6.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The California State Board of Registered Nursing accepts courses approved for the AMA PRA Category 1 Credits™ as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies.

Disclosure Statement

The FDA has issued a concept paper that classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is "truly independent" and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program's participants. In addition, Accreditation Council for Continuing Medical Education policy mandates that the provider adequately manage all identified potential conflicts of interest prior to the program. UCLA fully endorses the letter and spirit of these concepts.

UCLA Health it begins with U

Center for Continuing Professional Development UCLA David Geffen School of Medicine BOX 956938, 885 Tiverton Drive, Suite 300 Los Angeles, CA 90095-6938 The UCLA Heart Failure, Mechanical Support and Heart Transplant Team presents

UCLA Heart Failure Symposium 2025

State-of-the-Art Updates & Therapies for Advanced Heart Failure

A Hybrid CME Conference

Available as both a live in-person and live virtual activity

Saturday, September 20, 2025 Register today!

NON-PROFIT ORG.
U.S. POSTAGE
PAID
UNIVERSITY OF CALIFORNIA,
LOS ANGELES